Clinical Trial Search

Primary: Sensitivity(mtmDR) — 90.48; 95.65; 95.19 percentage of true positives

Primary: Sensitivity Corrected for Enrichment — 87.2 percentage of true positives

Primary: Increase in Acid Sphingomyelinase (ASM) Expression and Activity in Bone Marrow-derived Endothelial Progenitor Cells (EPCs) — 0.2; 0.5 nM/hr

Primary: Number of Participants With Progression of Diabetic Retinopathy of at Least 3 Stages on the Early Treatment Diabetic Retinopathy Study (ETDRS) Scale, or Development of…

Primary: Percentage of Subjects With Vision Loss to 20/40 or Worse — 5; 3 Eyes — p=.76

Primary: Number of Participants With a 3-step or Greater Increase in Early Treatment of Diabetic Retinopathy Study (EDTRS) Severity Scale — 127; 124 Participants — p=0.8487

Primary: Number of Participants With a 3-step or Greater Increase in Early Treatment of Diabetic Retinopathy Study (EDTRS) Severity Scale — 161; 182 Participants — p=0.1994

Primary: Number of Participant Who Had Baseline Eye Exam — 33 Participants

Primary: The Mean Percentage Change of the Area of the Patient's Neovascularization as Measured in Pixels by Optomap FA (Fluorescein Angiography) — -83.8; 52.6; 11.3; 55.4…

Primary: Number of Participants With a 2-step or Greater Increase in Early Treatment Diabetic Retinopathy Study (ETDRS) Severity Scale. — 178; 217 Participants — p=0.0508

Primary: Percentage of Participants With Any Ocular Adverse Events Over the On-treatment Period — 35.0; 23.1 Percentage of participants

Primary: Percentage of Participants With Improvement in DRSS by ≥ 2 Steps at 48 Weeks of Treatment in the Study Eye — 0.0; 1.9 percentage of participants

Primary: Proportion of Participants With >/= 2-Step Improvement in the Early Treatment Diabetic Retinopathy Study (ETDRS) DR Severity Scale (DRSS) From Baseline at Week 36…

Primary: The Mean Change in the Foveal Sensitivity of Matrix Frequency Doubling Perimetry (FDP) From Baseline in the Treated Group Compared to the Placebo Group — 2.80; 0.13 dB

Primary: Proportion of Participants Who Improved by ≥ 2 Steps From Baseline in Diabetic Retinopathy Severity Scale (DRSS) Scores — 12.187; 12.263; 13.311 estimated improvement…

Primary: Change in Dark Adaptation, Rod Intercept — 0.3; -0.3 minutes — p=.70

Primary: Mean Change in Visual Acuity From Baseline — 2.8; 0.2 letters

Primary: Change in Electronic Early Treatment Diabetic Retinopathy Study Visual Acuity Letter Score From Baseline to 14 Weeks — -4; 1; 2 Letter Score — p=<.001

Primary: Correlation Between Change in Level of Propermeability Factors With Change in Edema After Treatment With a Dexamethasone Implant or Anti-VEGF Agent — 0.47; 0.059; 0.45…

Primary: The Best Corrected Visual Acuity (BCVA) — 67.6; 76.36 letters — p=<0.0001

Primary: Proportion of Subjects Who Gain Two or More Lines in Best Corrected Visual Acuity(BCVA) Score in the Study Eye Compared With Baseline. — 3; 18 participants

Primary: Development of PDR and/or DME (Whichever Came First) — 27; 75 Eyes

Primary: Rate of Resolved Post-operative Vitreous Hemorrhage. — 6; 5 Participants

Primary: Rates of Retina Care Referral for Patients With Diabetic Macular Edema — 44 Participants

Primary: Change in Measurement in Central Macular Thickness Measured by Spectral Domain Optical Coherence Tomography( OCT) at One Month — -25.2; -29.9; -58.9 micrometers — p=0.04

Primary: Number of Participants With Treatment-related Adverse Events as Assessed by CTCAE v4.0 — 0; 0; 0; 0 Participants

Primary: Mean Change in Early Treatment Diabetic Retinopathy Study (ETDRS) Best-corrected Visual Acuity (BCVA) From Baseline to 36 Weeks (Crossover Phase of the Study) — 5.3; 6.6…

Primary: Number of Participants Who Had Successful Referrals — 92; 44 Participants — p=<0.001

Primary: Change in Panretinal Leakage Index at Month 12 From Baseline — -3.14 percentage of region of interest in UWFA

Primary: Per Patient Referral Accuracy — 318 Participants